PROFICIENCY TESTING

PERFORMANCE EVALUATION
2024 Microbiology - 3rd Event
1159 Business Park Drive, Traverse City, MI 49686
Please check the reports carefully. Errors made by API will be corrected if
800-333-0958 (toll free) / +1 231-941-5887 (international) reported within 60 days of the final report date.
www.api-pt.com

Customer Information
API Customer Number: 79982 CLIA Number:
CLIA ID indicates results available to CMS.
Dra. Diana Cuenca Results also available to:
Clinica Tolima ,
Cra 1 No. 12-22
Tolima
Ibague,
Colombia

The American Proficiency Institute evaluation reports consist of four parts : Report Cover, Performance Summary, Comparative Evaluation, and Participant Data
Summary. The Performance Summary and Comparative Evaluation are enclosed, and the Participant Data Summary is available on our website. Click on 'Participant
Data Summaries' on the left side of the screen, choose a Test Event, and select an analyte and peer group to view the statistics.

Laboratories should review the Performance Summary and Comparative Evaluation thoroughly for failures or 'not graded' analytes. Laboratories are responsible for
documenting and performing corrective action for failures and must perform a self-evaluation using statistics presented in the Participant Data Summary for samples
that have not been graded.

PERFORMANCE REVIEW AND CORRECTIVE ACTION

After reviewing the evaluation reports, complete the information below and retain this form along with the enclosed reports for your records.

Reviewed by (Lab Director or designee): Date:

Corrective action taken (if indicated):

API Program Coordinator: Final Report - 10/30/2024

Anita Hoeksema: [email protected] Authorized by: Leigh Akerley
Technical Director
Part 1 of 4, Page 1 of 1
 Customer No: 79982
CLIA No: Not on file
Address: Dra. Diana Cuenca
Clinica Tolima
1159 Business Park Drive, Traverse City, MI 49686 Cra 1 No. 12-22
Performance Summary Tolima
Ibague,
2024 Microbiology - 3rd Event
This is a summary of your proficiency testing performance for the last three test events. It is divided into sections according to specialty/sub-specialty. Unsuccessful long-term
performance, where indicated, is based on unsatisfactory scores for two of three test events.

The scores for individual analytes are defined as the ratio of acceptable responses to the number of samples tested, expressed as a percentage. Unsatisfactory performance
(denoted by ü) is indicated for any analyte with less than 80%. Analytes that are scored for CMS are designated by (**).

Microbiology scores are reported to CMS by sub-specialty, not by analyte. Microbiology sub-specialties with scored challenges have CMS sub-specialty scores shown to the right
of the sub-specialty headings. These scores are the ratio of acceptable responses for all scored challenges in the sub-specialty to the total number of possible scored
responses, expressed as a percentage.

MICROBIOLOGY 2024 1st 2024 2nd 2024 3rd Long Term Notes (2024 3rd)
Bacteriology 94% 100% 100%
Gram Stain ** 100% 100% 100%
Gram Stain Morphology 100% 100% 100%
Group A Strep Antigen ** 100% 100% 100%
MIC Value (UR) Educational Educational Educational
Susceptibility Testing (UR) ** 86% 100% 100%
Throat Culture ** 100% 100% 100%
Urine Colony Count 100% 100% 100%
Urine Identification ** 100% 100% 100%

MICROBIOLOGY 2024 1st 2024 2nd 2024 3rd Long Term Notes (2024 3rd)
Parasitology 100% 100% 100%
Parasitology ** 100% 100% 100%

MICROBIOLOGY 2024 1st 2024 2nd 2024 3rd Long Term Notes (2024 3rd)
Virology 100% 100% 100%
HPV Genotyping 100%
Human Papillomavirus ** 100%
SARS-CoV-2 (molecular) ** 100% 100% 100%

A-79982 Part 2 of 4, Page 1 of 1 10/29/2024

 Customer No: 79982 Kit No: 1
CLIA No: Not on file
Address: Dra. Diana Cuenca
1159 Business Park Drive, Traverse City, MI 49686
Clinica Tolima
ISO/IEC 17043 - Proficiency Testing Provider
Cra 1 No. 12-22
Comparative Evaluation Tolima
2024 Microbiology - 3rd Event Ibague,

This report shows the result you reported, expected result and your grade for each sample tested.

Analytes that are scored for CMS are designated by (**); scores for these analytes are sent to CMS and are used to determine the overall scores for each CMS
specialty/sub-specialty. Analytes designated by (^) are not included in API's scope of ISO/IEC 17043 accreditation.

GRAM STAIN
Analyte / Method Sample Reported Result Expected Result Performance
Gram Stain ** GS-11 Gram positive organism Gram positive organism Acceptable
GS-12 Gram negative organism Gram negative organism Acceptable
2
GS-13 Gram positive organism See Data Summary Not Graded
GS-14 Gram negative organism Gram negative organism Acceptable
GS-15 Gram negative organism Gram negative organism Acceptable
Gram Stain Morphology GS-11 Cocci Cocci Acceptable
GS-12 Rods / Bacilli Rods / Bacilli Acceptable
Coccobacilli
GS-13 Rods / Bacilli Rods / Bacilli Acceptable
GS-14 Diplococci Diplococci Acceptable
GS-15 Diplococci Diplococci Acceptable

PARASITOLOGY
Analyte / Method Sample Reported Result Expected Result Performance
Parasitology ** PAR-11 No parasites seen No parasites seen Acceptable
PAR-12 Giardia sp. Giardia duodenalis Acceptable
PAR-14 Fasciola hepatica/F. buski Fasciola hepatica/F. buski Acceptable
PAR-15 Microfilaria Wucheria bancrofti Acceptable

RAPID GROUP A STREP ANTIGEN

Analyte / Method Sample Reported Result Expected Result Performance
Group A Strep Antigen ** ST-11 Negative Negative Acceptable
Other product-please review ST-12 Positive Positive Acceptable

SARS-COV-2 (MOLECULAR)
Analyte / Method Sample Reported Result Expected Result Performance
SARS-CoV-2 (molecular) ** ^ SAR-11 Not Detected Not Detected Acceptable
Abbott ID Now COVID-19 SAR-12 Detected Detected Acceptable

THROAT CULTURE
Analyte / Method Sample Reported Result Expected Result Performance
Throat Culture ** TH-11 Positive for Group A Strep Positive for Group A Strep Acceptable
TH-12 Negative for Group A Strep Negative for Group A Strep Acceptable

URINE CULTURE & COLONY COUNT

Analyte / Method Sample Reported Result Expected Result Performance
Urine Colony Count UR-11 >100,000 CFU/mL >100,000 CFU/mL Acceptable
Alifax HB&L 10,000-100,000 CFU/mL

Urine Identification ** UR-11 Klebsiella pneumoniae Klebsiella pneumoniae Acceptable

Vitek 2

URINE CULTURE MIC/ZONE DIAMETER VALUE

Analyte / Method Sample Reported Result Expected Result Mean SD SDI Performance
MIC Value (UR) ^
3
MIC Vitek 2/CLSI / Amikacin UR-11 <1 See Data Summary Not Graded
3
MIC Vitek 2/CLSI / Ampicillin/Sulbactam UR-11 4.000 See Data Summary Not Graded
3
MIC Vitek 2/CLSI / Cefazolin UR-11 <4 See Data Summary Not Graded

A-79982 Part 3 of 4, Page 1 of 2

URINE CULTURE MIC/ZONE DIAMETER VALUE - continued
Analyte / Method Sample Reported Result Expected Result Mean SD SDI Performance
MIC Value (UR) ^
3
MIC Vitek 2/CLSI / Cefepime UR-11 < 0.12 See Data Summary Not Graded
3
MIC Vitek 2/CLSI / Ceftazidime UR-11 < 0.12 See Data Summary Not Graded
3
MIC Vitek 2/CLSI / Ceftriaxone UR-11 < 0.25 See Data Summary Not Graded
3
MIC Vitek 2/CLSI / Ciprofloxacin UR-11 < 0.06 See Data Summary Not Graded
3
MIC Vitek 2/CLSI / Ertapenem UR-11 < 0.12 See Data Summary Not Graded
3
MIC Vitek 2/CLSI / Gentamicin UR-11 <1 See Data Summary Not Graded
3
MIC Vitek 2/CLSI / Meropenem UR-11 < 0.25 See Data Summary Not Graded
3
MIC Vitek 2/CLSI / Nitrofurantoin UR-11 32.000 See Data Summary Not Graded
3
MIC Vitek 2/CLSI / Norfloxacin UR-11 < 0.5 See Data Summary Not Graded
3
MIC Vitek 2/CLSI / UR-11 < 0.2 See Data Summary Not Graded
Trimethoprim/Sulfamethoxazole

URINE CULTURE SUSCEPTIBILITY INTERPRETATION

Analyte / Method Sample Reported Result Expected Result Performance
Susceptibility Testing (UR) **
MIC Testing / CLSI / Amikacin UR-11 Susceptible Susceptible Acceptable

MIC Testing / CLSI / Ampicillin/Sulbactam UR-11 Susceptible Susceptible Acceptable

MIC Testing / CLSI / Cefazolin UR-11 Susceptible Susceptible Acceptable

MIC Testing / CLSI / Cefepime UR-11 Susceptible Susceptible Acceptable

MIC Testing / CLSI / Ceftazidime UR-11 Susceptible Susceptible Acceptable

MIC Testing / CLSI / Ceftriaxone UR-11 Susceptible Susceptible Acceptable

MIC Testing / CLSI / Ciprofloxacin UR-11 Susceptible Susceptible Acceptable

MIC Testing / CLSI / Ertapenem UR-11 Susceptible Susceptible Acceptable

MIC Testing / CLSI / Gentamicin UR-11 Susceptible Susceptible Acceptable

MIC Testing / CLSI / Meropenem UR-11 Susceptible Susceptible Acceptable

MIC Testing / CLSI / Nitrofurantoin UR-11 Susceptible Susceptible Acceptable

Intermediate

MIC Testing / CLSI / Norfloxacin UR-11 Susceptible Susceptible Acceptable

MIC Testing / CLSI / UR-11 Susceptible Susceptible Acceptable

Trimethoprim/Sulfamethoxazole

2 - No Consensus
3 - See Data Summary

A-79982 Part 3 of 4, Page 2 of 2